Oncology was Dr Reddys Laboratories’s largest revenue line in fiscal 2026, bringing in $68.31B of $333.81B (20%).
| Products And Services | FY 2021 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Oncology | $52.92B | $71.12B | $89.20B | $68.31B | |
| Central Nervous System | $31.64B | $32.67B | $47.07B | $65.38B | |
| Pain Management | $27.31B | $28.21B | $31.22B | $34.04B | |
| Gastrointestinal | $24.50B | $24.48B | $26.54B | $28.54B | |
| Cardiovascular | $22.81B | $24.21B | $25.61B | $26.43B | |
| Other Global Generics | $12.03B | $21.60B | $27.55B | $23.68B | |
| Respiratory | $17.88B | $17.23B | $17.70B | $22.41B | |
| Anti-Infective | $17.07B | $15.90B | $12.77B | $13.20B | |
| Hematology | $10.74B | $11.60B | $11.09B | $10.10B | |
| Diabetology | $5.89B | $6.95B | $9.49B | $14.24B | |
| Dermatology | $7.47B | $6.54B | $7.17B | $8.69B | |
| Nutraceutical | $5.88B | $7.69B | $9.13B | $8.02B | |
| Other Psai | $3.71B | $5.25B | $6.78B | $8.56B | |
| Anti Infective One | $2.35B | $1.46B | $1.68B | $1.74B | |
| Genitourinary | $637.00M | $367.00M | $416.00M | $475.00M | |
| Total | $242.84B | $275.25B | $323.40B | $333.81B |
Dr Reddys Laboratories brought in $333.81B from its 15 revenue lines in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $323.40B in fiscal 2025. Oncology was the largest at $68.31B (20.5%), ahead of Central Nervous System at $65.38B (19.6%) and Pain Management at $34.04B (10.2%). The other 12 revenue lines brought in $166.08B combined.
Compared with fiscal 2025, Diabetology grew fastest, up 50.0% to $14.24B, while Oncology fell the most, down 23.4% to $68.31B. From fiscal 2023 to 2026, combined revenue from these revenue lines grew from $242.84B to $333.81B, a compound annual growth rate of 11.2%. Oncology's share of the total fell from 21.8% to 20.5%.
Others was Dr Reddys Laboratories’s largest region in fiscal 2026, bringing in $118.72B of $335.93B (35%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $106.68B | $135.57B | $149.35B | $117.89B | ||||||
| Oncology | — | — | — | — | ||||||
| United States Country | — | — | — | — | ||||||
| Others | $67.47B | $72.83B | $94.40B | $118.72B | ||||||
| India | $50.50B | $48.47B | $55.83B | $64.54B | ||||||
| Russia | $21.23B | $22.30B | $25.96B | $34.79B | ||||||
| Total | $245.88B | $279.16B | $325.54B | $335.93B |
Dr Reddys Laboratories brought in $335.93B from its four regions in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $325.54B in fiscal 2025. Others was the largest at $118.72B (35.3%), ahead of United States at $117.89B (35.1%) and India at $64.54B (19.2%). The remaining region, Russia, brought in $34.79B.
Compared with fiscal 2025, Russia grew fastest, up 34.0% to $34.79B, while United States fell the most, down 21.1% to $117.89B. From fiscal 2023 to 2026, combined revenue from these regions grew from $245.88B to $335.93B, a compound annual growth rate of 11.0%. Others' share of the total rose from 27.4% to 35.3%.
Global Generic was Dr Reddys Laboratories’s largest segment in fiscal 2026, bringing in $299.03B of $335.93B (89%).
| Segments [axis] | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Generic | $213.77B | $245.45B | $289.55B | $299.03B | |||||||
| Pharmaceutical Services & Active Ingredient | $29.07B | $29.80B | $33.85B | $34.77B | |||||||
| Psai | — | — | — | — | |||||||
| Proprietary Product | — | — | — | — | |||||||
| Other Segment | $3.04B | $3.91B | $2.14B | $2.13B | |||||||
| Total | $245.88B | $279.16B | $325.54B | $335.93B |
Dr Reddys Laboratories brought in $335.93B from its three segments in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $325.54B in fiscal 2025. Global Generic was the largest at $299.03B (89.0%), ahead of Pharmaceutical Services & Active Ingredient at $34.77B (10.4%) and Other Segment at $2.13B (0.6%).
Compared with fiscal 2025, Global Generic grew 3.3% to $299.03B and Pharmaceutical Services & Active Ingredient grew 2.7% to $34.77B. From fiscal 2023 to 2026, combined revenue from these segments grew from $245.88B to $335.93B, a compound annual growth rate of 11.0%. Global Generic's share of the total rose from 86.9% to 89.0%.
Dr Reddys Laboratories (RDY) reports its revenue by products and services, by geography and by segments [axis]. In fiscal 2026, Oncology was its largest revenue line, bringing in $68.31B (20.5% of the total), followed by Central Nervous System at $65.38B (19.6%).
Oncology was Dr Reddys Laboratories' largest revenue line in fiscal 2026, bringing in $68.31B, or 20.5% of the $333.81B total across its 15 revenue lines.
Others was Dr Reddys Laboratories' largest region in fiscal 2026, bringing in $118.72B, or 35.3% of the $335.93B total across its four regions.
Global Generic was Dr Reddys Laboratories' largest segment in fiscal 2026, bringing in $299.03B, or 89.0% of the $335.93B total across its three segments.
Among Dr Reddys Laboratories' revenue lines that make up at least 2% of revenue, Diabetology grew fastest in fiscal 2026, up 50.0% from $9.49B to $14.24B.
Every figure comes from Dr Reddys Laboratories' annual financial filings, as reported. Each line keeps the name Dr Reddys Laboratories gives it, and years follow its fiscal calendar.
Dr Reddys Laboratories' revenue by products and services goes back to fiscal 2021, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.